Prove ADCC Activity in Real Human Skin

For therapies targeting mast cells, demonstrating antibody-dependent cell-mediated cytotoxicity (ADCC) in complex human tissue is essential. Traditional in vitro assays provide limited context, leaving critical aspects of biological impact unclear.

HypoSkin^® offers a solution
Our ex vivo human skin model lets you assess mast cell depletion in situ, offering a powerful, human-relevant platform to confirm the effects of engineered antibodies.

A recent study showed how HypoSkin helped validate Fc-enhanced anti-KIT antibodies for mastocytosis—revealing functional immune engagement at the tissue level.

Don’t just bind—deplete.
Download the study poster to see how HypoSkin can help you:

• Demonstrate tissue-level ADCC
• De-risk early immunotherapy development

Translate in vitro findings into clinical relevance